HIV Mutation Detail Information

> K103N Search Result


Mutation Information
Mutation Site K103N
Mutation Type Amino acid level
Gene/Protein/Region Type RT
Relevant Drug lamivudine (LAM)
Country Kenya
Literature Information
PubMed PMID 31818716
Disease HIV infection/AIDS
Published Year 2020
Journal The lancet. HIV
Title Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.
Author Chung MH,McGrath CJ,Beck IA,Levine M,Milne RS,So I,Andersen N,Dross S,Coombs RW,Chohan B,Yatich N,Kiptinness C,Sakr SR,Kiarie JN,Frenkel LM
Evidence The OLA-guided therapy group had pre-ART peripheral blood mononuclear cells evaluated for drug resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) at codons Lys103Asn, Tyr181Cys, Gly190Ala, and to lamivudine at Met184Val, and when at least one drug-resistant codon was detected in a participant's pre-ART specimen, clinicians were directed to prescribe protease inhibitor-based second-line ART.

Contents
Description
Mutation Information Note
  • Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)
Literature Information Note
  • Evidence: sentence contains this mutation information in the citation